| Literature DB >> 31297191 |
Norihisa Yamamoto1,2, Shigeto Hamaguchi1,2, Yukihiro Akeda1,2, Pitak Santanirand3, Narong Chaihongsa3, Suntariya Sirichot3, Suwichak Chiaranaicharoen3, Hideharu Hagiya1,2, Kouji Yamamoto4, Anusak Kerdsin5, Kazuhisa Okada2, Hisao Yoshida1, Shigeyuki Hamada2, Kazunori Oishi6, Kumthorn Malathum3, Kazunori Tomono1.
Abstract
Background: Active surveillance has the potential to prevent nosocomial transmission of carbapenem-resistant Acinetobacter baumannii (CRAB). We assessed whether rapid diagnosis using clinical specimen-direct loop-mediated isothermal amplification (LAMP), a rapid molecular diagnostic assay, and subsequent intervention, could reduce CRAB nosocomial transmission in intensive care units (ICUs).Entities:
Keywords: Carbapenem-resistant Acinetobacter baumannii (CRAB); LAMP (Loop-mediated isothermal amplification), Rapid molecular diagnosis.; Nosocomial transmission; Rapid intervention, Intensive care unit.
Mesh:
Substances:
Year: 2019 PMID: 31297191 PMCID: PMC6598269 DOI: 10.1186/s13756-019-0564-9
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Risk factors associated with carriage of carbapenem-resistant Acinetobacter baumannii (CRAB) on admission to ICUs
| Characteristics | Odds Ratio (95% CI) |
|
|---|---|---|
| Female Sex | 1.02 (0.68–1.53) | 0.93 |
| Age | 1.02 (1.00–1.03) | 0.78 |
| History of hospitalization within 90 days | 2.85 (1.91–4.26) | < 0.001 |
| History of CRAB-positive within 90 days | 60.8 (29.7–125) | < 0.001 |
| Circulatory disease | 1.20 (0.73–1.97) | 0.58 |
| Chronic kidney disease | 1.28 (0.78–2.10) | 0.38 |
| Gastrointestinal disease | 1.64 (0.80–3.37) | 0.18 |
| Chronic respiratory disease | 1.35 (0.80–2.30) | 0.26 |
| Hepatobiliary disease | 0.89 (0.32–2.45) | 0.82 |
| Cerebral vascular disease | 0.77 (0.30–1.96) | 0.58 |
| Malignancy (hematologic malignancies and solid tumor) | 0.75 0.45–1.27) | 0.30 |
| Hypertension | 0.85 (0.52–1.39) | 0.51 |
| Diabetes mellitus | 0.78 (0.45–1.34) | 0.37 |
| Autoimmune disease | 1.65 (0.65–4.16) | 0.29 |
CI confidence interval
Fig. 1Flowchart for patient selection in this study
Characteristics of patients eligible for this study
| Characteristics | Pre-interventional Period ( | Interventional Period ( | Total ( |
|
|---|---|---|---|---|
| Female Sex | 93 (49.7%) | 315 (46.4%) | 408 (47.1%) | 0.42 |
| Age, median years (IQR) | 66 (55, 78) | 64 (54, 77) | 65 (54, 77) | 0.46 |
| History of hospitalization within 90 days | 57 (30.5%) | 209 (30.8%) | 266 (30.7%) | 0.94 |
| History of CRAB positive within 90 days | 5 (2.7%) | 11 (1.6%) | 16 (1.8%) | 0.34 |
| Duration of ICU stay, median days (IQR) | 5 (3.5, 9) | 6 (4, 10) | 6 (4, 10) | 0.124 |
| Intubation | 132 (70.6%) | 460 (67.8%) | 592 (68.4%) | 0.48 |
| Circulatory disease | 38 (20.3%) | 115 (16.9%) | 153 (17.7%) | 0.28 |
| Chronic kidney disease | 34 (18.2%) | 123 (18.1%) | 157 (18.1%) | 0.98 |
| Gastrointestinal disease | 5 (2.7%) | 43 (6.3%) | 48 (5.5%) | 0.053 |
| Chronic respiratory disease | 28 (15.0%) | 87 (12.8%) | 115 (13.3%) | 0.44 |
| Hepatobiliary disease | 10 (5.3%) | 26 (3.8%) | 36 (4.2%) | 0.36 |
| Cerebral vascular disease | 8 (4.3%) | 55 (8.1%) | 63 (7.3%) | 0.075 |
| Malignancy (hematologic malignancies and solid tumor) | 41 (21.9%) | 188 (27.7%) | 229 (26.4%) | 0.114 |
| Hypertension | 85 (45.5%) | 225 (33.1%) | 310 (35.8%) | 0.002 |
| Diabetes mellitus | 62 (33.2%) | 160 (23.6%) | 222 (25.6%) | 0.008 |
| Autoimmune diseases | 9 (4.8%) | 28 (4.1%) | 37 (4.3%) | 0.68 |
| Infectious diseases | 62 (33.2%) | 167 (24.6%) | 229 (26.4%) | 0.019 |
IQR interquartile range
Risk factors associated with carbapenem-resistant Acinetobacter baumannii (CRAB) acquisition during hospitalization
| Characteristics | Hazard Ratio (95% CI) |
|
|---|---|---|
| Medical intervention | ||
| Intubation | 1.23 (0.71–2.15) | 0.46 |
| Central venous catheter | 0.69 (0.44–1.06) | 0.091 |
| Urinary Catheter | 0.69 (0.39–1.23) | 0.21 |
| Steroid exposure | 0.83 (0.53–1.29) | 0.41 |
| Antimicrobial exposure | ||
| Carbapenems | 2.54 (1.61–4.00) | < 0.0001 |
| Quinolones | 0.73 (0.40–1.34) | 0.31 |
| Penicillins | 1.34 (0.87–2.08) | 0.19 |
| 3rd and 4th generations of Cephalosporin | 0.69 (0.45–1.06) | 0.087 |
| Aminoglycosides | 1.59 (0.45–5.57) | 0.47 |
CI confidence interval
Fig. 2Kaplan-Meier curves representing cumulative incidence of acquiring carbapenem-resistant Acinetobacter baumannii during ICU stay. The hazard ratio (HR) was calculated by using the multivariable Cox proportional hazard analysis and HR of CRAB transmission was 0.65 (95% CI:0.44–0.97) in the interventional period compared with that in the pre-interventional period